Sichuan Duorui Biopharmaceutical

Chengdu-based maker of peptide and oligonucleotide APIs, founded in 2018, with lanreotide acetate in production and semaglutide, tirzepatide and retatrutide listed on its site as under development. Offers CDMO services. Holds active US Drug Master Files for lanreotide, semaglutide and tirzepatide API. Says its teriparatide injection pen line passed an FDA on-site audit; no FDA inspection is recorded under this name.

Directory assessment: Sichuan Duorui Biopharmaceutical is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Chengdu). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 2 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.